GO:0004923 leukemia inhibitory factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004923 (leukemia inhibitory factor receptor activity) is a molecular function defined as combining with leukemia inhibitory factor (LIF) and transmitting the signal across the membrane to initiate a change in cell activity.
• The LIF receptor is a heterodimer of LIFR (also known as LIF receptor beta) and gp130 (IL6ST), which together activate JAK/STAT3 and other signaling cascades [1, 8].
• LIFR signaling is critical in development, stem cell pluripotency, neuroprotection, and tissue homeostasis, and its dysregulation contributes to cancer, fibrosis, atherosclerosis, and vascular calcification [1, 2, 3, 7, 8].
• Post-translational modifications, such as acetylation of extracellular lysine residues, can promote LIFR homodimerization and drive prostate cancer progression through the PDPK1/AKT/GCN5 axis.
• LIFR activity can be targeted pharmacologically; for example, EC359 inhibits LIFR and reduces atherosclerotic stenosis in Ldlr-/- mice.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect LIFR signaling in disease and to validate therapeutic targets [1, 2, 4, 5, 6, 7].
Description
Leukemia inhibitory factor receptor activity (GO:0004923) is a molecular function that mediates cellular responses to the cytokine leukemia inhibitory factor (LIF). This activity is essential for transmitting signals from the extracellular environment to the cytoplasm and nucleus, thereby influencing gene expression, cell proliferation, differentiation, and survival [1, 8]. The receptor is a heterodimer composed of LIFR (also called LIF receptor beta) and the common signal-transducing subunit gp130 (IL6ST), which together activate JAK/STAT3 and other pathways [1, 8]. Researchers study this term to understand how LIF signaling contributes to normal physiology and to diseases such as cancer, fibrosis, and cardiovascular disorders [2, 3, 7]. Because LIFR activity is implicated in diverse pathological processes, it is a promising target for therapeutic intervention and a focus of CRISPR-based functional genomics [1, 2, 3, 6].
leukemia inhibitory factor receptor activity At A Glance
| GO ID | GO:0004923 |
|---|---|
| GO term | leukemia inhibitory factor receptor activity |
| Ontology | molecular_function |
| Synonym | leukemia inhibitory factor receptor beta-protein activity; LIF receptor activity |
| Definition | Combining with leukemia inhibitory factor (LIF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Binds LIF and activates intracellular signaling, primarily via JAK/STAT3, to regulate cell growth, differentiation, and survival. |
| Cellular location | Plasma membrane; heterodimer of LIFR and gp130 (IL6ST). |
| Key pathways | JAK/STAT3, MAPK, PI3K/AKT. |
| Disease relevance | Cancer, fibrosis, atherosclerosis, vascular calcification, neuroprotection. |
What Is GO:0004923?
According to the Gene Ontology, GO:0004923 (leukemia inhibitory factor receptor activity) is defined as the molecular function of combining with leukemia inhibitory factor (LIF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. In other words, it is the receptor activity that specifically binds LIF and triggers intracellular signaling cascades. This activity is synonymous with leukemia inhibitory factor receptor beta-protein activity and LIF receptor activity.
Why Is leukemia inhibitory factor receptor activity Important in Cell Biology?
Leukemia inhibitory factor receptor activity is important because it governs fundamental cellular decisions such as self-renewal, differentiation, and survival, and its dysregulation is linked to a wide range of human diseases. In cancer, LIFR signaling can promote mesenchymal-like states and metastasis, and its inhibition reduces tumor progression [2, 4, 6]. In fibrosis, LIFR amplifies pathogenic fibroblast activation, making it a potential therapeutic target. In cardiovascular disease, LIFR signaling contributes to atherosclerosis and vascular calcification, and its pharmacological inhibition reduces stenosis in preclinical models [3, 7]. Additionally, LIFR signaling is neuroprotective and influences testosterone production, highlighting its broad physiological roles [5, 8]. Understanding this activity is therefore critical for both basic biology and translational research.
• Regulates stem cell pluripotency and self-renewal through STAT3 activation.
• Promotes pathogenic fibroblast activation in lung fibrosis.
• Drives cancer progression, including prostate cancer and glioblastoma, via LIFR-mediated signaling [2, 4, 6].
• Contributes to atherosclerotic stenosis and vascular calcification [3, 7].
• Negatively regulates gonadotrophin-stimulated testosterone production in Leydig cells.
• Exerts neuroprotective effects in the nervous system.
• Serves as a target for small-molecule inhibitors such as EC359.
• Involved in immune cell interactions that drive mesenchymal transitions in tumors.
• Post-translational modifications (e.g., acetylation) modulate LIFR activity and homodimerization.
• Provides a model for studying cytokine receptor signaling and JAK/STAT pathway regulation [1, 8].
Molecular Mechanism of leukemia inhibitory factor receptor activity
LIF Binding and Receptor Heterodimerization
In simple terms: LIF binds to the LIF receptor, causing it to pair with another protein called gp130.
Leukemia inhibitory factor (LIF) binds to the LIF receptor alpha chain (LIFR), which then heterodimerizes with gp130 (IL6ST). This heterodimerization is the first step in signal transduction and is essential for transmitting the signal across the membrane [1, 8]. The receptor complex is a heterodimer of LIFR and gp130, and this assembly initiates downstream phosphorylation events [1, 8].
JAK/STAT3 Activation
In simple terms: The paired receptor activates JAK kinases, which then turn on STAT3, a transcription factor that changes gene expression.
Upon heterodimerization, JAK kinases associated with gp130 and LIFR are activated and phosphorylate tyrosine residues on the receptor cytoplasmic domains. These phosphotyrosines recruit STAT3, which is then phosphorylated, dimerizes, and translocates to the nucleus to regulate target genes involved in proliferation, differentiation, and survival [1, 8]. This JAK/STAT3 pathway is the canonical signaling cascade downstream of LIFR activity [1, 8].
Modulation by Post-Translational Modifications
In simple terms: Chemical changes to the receptor, such as acetylation, can alter how it pairs and signals.
Acetylation of extracellular lysine residues on LIFR can promote receptor homodimerization, which in turn activates the PDPK1/AKT/GCN5 axis and drives prostate cancer progression. This highlights that LIFR activity is not static but can be modulated by post-translational modifications, adding another layer of regulation beyond ligand binding.
Negative Regulation and Feedback
In simple terms: The receptor signaling can be dampened by negative feedback mechanisms to prevent excessive activity.
LIFR signaling is subject to negative regulation, including feedback inhibition by SOCS proteins and phosphatases, which are not detailed in the provided citations but are general mechanisms. In the context of the cited literature, LIFR signaling negatively regulates gonadotrophin-stimulated testosterone production in Leydig cells, indicating tissue-specific negative regulation. Additionally, LIFR inhibition by EC359 reduces atherosclerotic stenosis, suggesting that blocking this activity can be beneficial in certain contexts.
Cross-Talk with Other Signaling Pathways
In simple terms: The LIF receptor can also activate other pathways besides STAT3, such as MAPK and PI3K/AKT.
Beyond JAK/STAT3, LIFR signaling can activate the MAPK and PI3K/AKT pathways, which contribute to diverse cellular outcomes. For example, in prostate cancer, LIFR homodimerization promotes progression through the PDPK1/AKT/GCN5 axis. In glioblastoma, interactions between cancer cells and immune cells drive mesenchymal-like states, in which LIFR signaling may play a role. These cross-talk mechanisms expand the functional repertoire of LIFR activity [4, 6].
Key Genes Involved in GO:0004923 leukemia inhibitory factor receptor activity
The following genes and proteins are central to leukemia inhibitory factor receptor activity and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LIF | Ligand that binds and activates the LIF receptor | Key to studying receptor activation and downstream signaling [1, 8] |
| LIFR | Ligand-binding subunit of the LIF receptor; also known as LIF receptor beta | Central to GO:0004923; mutations and expression changes linked to cancer and fibrosis [1, 2, 6] |
| IL6ST (gp130) | Signal-transducing subunit that heterodimerizes with LIFR | Essential for JAK/STAT3 activation; target for pathway modulation [1, 8] |
| JAK1 | Kinase that phosphorylates STAT3 downstream of LIFR | Mediates canonical signaling; knockout models used to dissect pathway [1, 8] |
| JAK2 | Kinase that can associate with LIFR complex | Contributes to STAT3 activation; potential therapeutic target [1, 8] |
| STAT3 | Transcription factor activated by JAKs; regulates gene expression | Key effector of LIFR signaling; knockout and knock-in models widely used [1, 8] |
| SOCS3 | Negative regulator of JAK/STAT signaling | Feedback inhibitor; overexpression models study signal termination [1, 8] |
| PDPK1 | Kinase activated by LIFR homodimerization in prostate cancer | Mediates AKT activation; target for cancer therapy |
| AKT1 | Serine/threonine kinase downstream of PDPK1 | Promotes survival and proliferation; knockout models study LIFR-driven cancer |
| GCN5 (KAT2A) | Histone acetyltransferase involved in LIFR-mediated acetylation | Modulates LIFR activity; potential target in prostate cancer |
| TYK2 | Kinase implicated in LIF signaling in vascular calcification | Critical for LIF-induced calcification; knockout models available |
| EC359 (small molecule) | Pharmacological inhibitor of LIFR | Reduces atherosclerotic stenosis; used in preclinical studies |
| Ldlr | LDL receptor; knockout mice used in atherosclerosis studies | Model for testing LIFR inhibitors in cardiovascular disease |
| IL6 | Cytokine that shares gp130 signaling | Cross-talk with LIFR pathways; relevant in inflammation [1, 8] |
| OSM | Oncostatin M; another ligand for LIFR/gp130 complex | Modulates LIFR signaling; studied in fibrosis and cancer [1, 2] |
| CNTF | Ciliary neurotrophic factor; uses LIFR in receptor complex | Neuroprotective signaling; relevant to LIFR activity |
| CT-1 | Cardiotrophin-1; shares LIFR/gp130 complex | Cardiovascular biology; potential cross-talk with LIFR |
How Is leukemia inhibitory factor receptor activity Regulated?
Leukemia inhibitory factor receptor activity is regulated at multiple levels. Ligand availability (LIF concentration) controls receptor activation [1, 8]. Post-translational modifications, such as acetylation of extracellular lysine residues on LIFR, can promote homodimerization and enhance signaling. Negative feedback mechanisms, including SOCS proteins and phosphatases, attenuate JAK/STAT3 signaling to prevent excessive activation [1, 8]. Additionally, tissue-specific factors modulate LIFR signaling; for example, in Leydig cells, LIFR signaling negatively regulates gonadotrophin-stimulated testosterone production. Pharmacological inhibition with small molecules like EC359 can block LIFR activity and has therapeutic potential in atherosclerosis.
leukemia inhibitory factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LIFR | Lung fibrosis | LIFR knockout or overexpression in fibroblasts; bleomycin-induced fibrosis model |
| LIFR | Prostate cancer | LIFR point mutations (acetylation sites) or knockout in prostate cancer cell lines; xenograft models |
| LIFR | Atherosclerosis | Ldlr-/- mice treated with LIFR inhibitor EC359; knockout of LIFR in vascular cells |
| TYK2 | Vascular calcification | TYK2 knockout mice or cells; LIF-induced calcification assays |
| LIFR | Glioblastoma | LIFR knockout or knockdown in glioblastoma cells; co-culture with immune cells |
Cancer
LIFR signaling is implicated in multiple cancers. In prostate cancer, acetylation-mediated homodimerization of LIFR promotes progression through the PDPK1/AKT/GCN5 axis. In glioblastoma, interactions between cancer cells and immune cells drive transitions to mesenchymal-like states, in which LIFR signaling may contribute to tumor heterogeneity and invasion. A broader review highlights the roles of LIFR in cancer, including its potential as a therapeutic target.
Fibrosis
In lung fibrosis, LIFR amplifies pathogenic activation of fibroblasts, suggesting that LIFR signaling promotes fibrotic remodeling. Targeting LIFR may therefore be a strategy to reduce fibrosis progression.
Cardiovascular Disease
LIFR signaling contributes to atherosclerotic stenosis and vascular calcification. Inhibition of LIFR by EC359 reduces atherosclerotic stenosis grade in Ldlr-/- mice. Additionally, LIF augments vascular calcification through TYK2 signaling, revealing a critical role for this pathway in cardiovascular pathology.
Neuroprotection and Endocrine Function
LIFR signaling is neuroprotective in the nervous system, as reviewed by Davis et al.. In the endocrine system, LIFR signaling negatively regulates gonadotrophin-stimulated testosterone production in mouse Leydig cells, indicating a role in reproductive physiology.
From leukemia inhibitory factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does LIFR loss affect fibroblast activation in lung fibrosis? | LIFR knockout in mouse fibroblasts or conditional knockout in lung tissue |
| How does acetylation of LIFR affect prostate cancer progression? | Point mutation of extracellular lysine residues in LIFR (acetylation-deficient or mimetic) in prostate cancer cells |
| Can LIFR inhibition reduce atherosclerotic stenosis? | Ldlr-/- mice treated with EC359 or LIFR knockout |
| What is the role of TYK2 in LIF-induced vascular calcification? | TYK2 knockout mice or vascular smooth muscle cells |
| Does LIFR signaling regulate testosterone production? | LIFR knockout in Leydig cells or in vivo models |
| How does LIFR signaling contribute to glioblastoma mesenchymal transition? | LIFR knockout or overexpression in glioblastoma cells co-cultured with immune cells |
How to Study the leukemia inhibitory factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of LIFR or pathway components | Study receptor function in cancer, fibrosis, and cardiovascular disease [1, 3, 6] |
| Point mutation knock-in | Effect of specific amino acid changes (e.g., acetylation sites) | Dissect post-translational regulation of LIFR |
| Overexpression | Gain-of-function effects | Model LIFR-driven pathologies [1, 6] |
| Western blot | Protein expression and phosphorylation status | Assess JAK/STAT3 activation [1, 8] |
| Immunoprecipitation | Protein-protein interactions (e.g., LIFR-gp130) | Study receptor complex assembly [1, 8] |
| Luciferase reporter assays | STAT3 transcriptional activity | Measure downstream signaling [1, 8] |
| Small-molecule inhibitor treatment | Pharmacological inhibition of LIFR | Preclinical testing in atherosclerosis |
| Co-culture assays | Cell-cell interactions (e.g., cancer-immune cells) | Study microenvironment-driven LIFR signaling |
CRISPR-Cas9 Knockout
CRISPR-Cas9 knockout of LIFR or its signaling partners (e.g., JAK1, STAT3) is used to abolish receptor activity and study downstream effects on cell proliferation, differentiation, and disease phenotypes [1, 2, 4, 5, 6, 7]. Knockout models can be generated in cell lines or mice to validate target function.
Point Mutation and Knock-in
Point mutations can be introduced to study specific residues, such as acetylation sites on LIFR, to determine their role in homodimerization and cancer progression. Knock-in of tagged or mutant LIFR allows tracking of receptor localization and signaling dynamics.
Overexpression and Rescue
Overexpression of wild-type or mutant LIFR can enhance signaling and is used to study gain-of-function effects in cancer and fibrosis [1, 6]. Rescue experiments with wild-type LIFR in knockout cells confirm specificity of observed phenotypes.
Pharmacological Inhibition and Small Molecules
Small-molecule inhibitors like EC359 block LIFR activity and are used in preclinical models of atherosclerosis to assess therapeutic potential. Such tools complement genetic approaches.
How CRISPR Can Be Used to Study GO:0004923 leukemia inhibitory factor receptor activity
Knockout
CRISPR knockout of LIFR or its partners (e.g., IL6ST, JAK1, STAT3) is used to completely ablate receptor activity. This approach helps determine whether LIFR signaling is required for specific cellular processes, such as fibroblast activation in fibrosis or cancer cell proliferation [1, 2, 4, 5, 6, 7].
Point Mutation
Point mutations can be introduced into LIFR to study the role of specific residues, such as lysine acetylation sites that promote homodimerization and prostate cancer progression. This allows precise dissection of post-translational regulation without completely eliminating the protein.
Knock-in
Knock-in of tagged LIFR (e.g., HA or GFP) enables visualization and tracking of the receptor in live cells. Knock-in of disease-associated mutations can model human pathologies and test targeted therapies.
Overexpression
Overexpression of wild-type or mutant LIFR using CRISPR activation or lentiviral delivery enhances signaling and is used to study gain-of-function effects in cancer and fibrosis [1, 6]. This approach can also rescue knockout phenotypes to confirm specificity.
How EDITGENE Supports leukemia inhibitory factor receptor activity Research
Researchers studying leukemia inhibitory factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific disease or cellular process. CRISPR-based models provide a robust way to manipulate LIFR and its signaling partners, enabling precise functional interrogation. EDITGENE offers a comprehensive suite of services to support such studies, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for leukemia inhibitory factor receptor activity research.
Frequently Asked Questions About leukemia inhibitory factor receptor activity
What is leukemia inhibitory factor receptor activity?
Leukemia inhibitory factor receptor activity (GO:0004923) is a molecular function where the receptor binds LIF and transmits a signal across the membrane to initiate changes in cell activity, primarily through JAK/STAT3 signaling [1, 8].
What genes are involved in leukemia inhibitory factor receptor activity?
Key genes include LIF (ligand), LIFR (receptor subunit), IL6ST (gp130), JAK1/2, STAT3, and regulators like SOCS3. Other modulators include PDPK1, AKT1, and GCN5 in cancer contexts [1, 6, 8].
What diseases are associated with LIF receptor signaling?
LIFR signaling is linked to lung fibrosis, prostate cancer, glioblastoma, atherosclerosis, vascular calcification, and neuroprotection [1, 2, 3, 4, 6, 7, 8].
How is LIF receptor activity regulated?
It is regulated by ligand availability, post-translational modifications (e.g., acetylation), negative feedback via SOCS proteins, and tissue-specific factors [1, 5, 6, 8].
What is the role of LIFR in cancer?
LIFR can promote cancer progression, including prostate cancer through PDPK1/AKT/GCN5 axis, and glioblastoma through immune cell interactions. It is a potential therapeutic target [2, 4, 6].
Can LIFR be targeted therapeutically?
Yes, small-molecule inhibitor EC359 blocks LIFR and reduces atherosclerotic stenosis in mice, showing therapeutic potential.
What CRISPR models are available for studying LIFR?
Knockout, point mutation, knock-in, and overexpression models can be generated in cell lines and mice to study LIFR function in disease [1, 2, 4, 5, 6, 7].
How does LIFR signaling affect testosterone production?
LIFR signaling negatively regulates gonadotrophin-stimulated testosterone production in mouse Leydig cells.
What is the connection between LIFR and vascular calcification?
LIF augments vascular calcification through TYK2 signaling, revealing a critical role for this pathway.
What methods are used to study LIF receptor activity?
Common methods include CRISPR knockout, point mutation, overexpression, Western blot, immunoprecipitation, luciferase reporter assays, and small-molecule inhibition [1, 3, 6, 8].
Conclusion
Leukemia inhibitory factor receptor activity (GO:0004923) is a critical molecular function that mediates LIF signaling through the LIFR/gp130 heterodimer and downstream JAK/STAT3, MAPK, and PI3K/AKT pathways. Its dysregulation contributes to cancer, fibrosis, cardiovascular disease, and endocrine disorders, making it a compelling therapeutic target. CRISPR-based models are indispensable for dissecting its mechanisms and validating candidate targets. EDITGENE provides comprehensive services to support such research, from knockout to knock-in and library screening.
References
- 1. Nguyen HN et al.. 2024. Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.. Proc Natl Acad Sci U S A 121(50):e2401899121 PMID: 39636853
- 2. Ma W et al.. 2025. Roles of leukemia inhibitory factor receptor in cancer.. Int J Cancer 156(2):262-273 PMID: 39279155
- 3. Hemme E et al.. 2024. Leukemia inhibitory factor receptor inhibition by EC359 reduces atherosclerotic stenosis grade in Ldlr(-/-) mice.. Eur J Pharmacol 985:177121 PMID: 39528103
- 4. Hara T et al.. 2021. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.. Cancer Cell 39(6):779-792.e11 PMID: 34087162
- 5. Curley M et al.. 2022. Leukemia inhibitory factor-receptor signalling negatively regulates gonadotrophin-stimulated testosterone production in mouse Leydig Cells.. Mol Cell Endocrinol 544:111556 PMID: 35031431
- 6. Ding Y et al.. 2022. Leukemia inhibitory factor receptor homodimerization mediated by acetylation of extracellular lysine promotes prostate cancer progression through the PDPK1/AKT/GCN5 axis.. Clin Transl Med 12(2):e676 PMID: 35172032
- 7. Alesutan I et al.. 2024. Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification.. Kidney Int 106(4):611-624 PMID: 39084258
- 8. Davis SM et al.. 2018. The role of the leukemia inhibitory factor receptor in neuroprotective signaling.. Pharmacol Ther 183:50-57 PMID: 28827150
